However, a longer interval between COVID-19 infection and the first vaccine dose was correlated with higher antibody levels. Longer dosing intervals did not significantly affect the healthcare workers who had previously contracted COVID-19. This observation was more pronounced in younger participants. Participants who received their second dose more than 2 weeks and less than 4 weeks after the first had antibody levels that averaged 1268.72, while infection naïve participants who received their second dose more than 10 weeks after the first averaged antibody levels of 11479.73. Notably, infection naïve individuals with a longer interval between doses had antibody levels up to 9 times higher. Over 99% of participants who had not had previously had COVID-19 successfully seroconverted after vaccination.Īfter the first Pfizer-BioNTech dose, participants with prior infection had antibody levels up to 10 times higher than the naïve individuals after dose 2, previously infected participants had antibody levels that averaged more than twice as high as those without prior infection. Participants were categorized as either a history of COVID-19 infection (confirmed by PCR test or antibody profile), or infection naïve. 1882 healthcare workers had their second dose at least 14 days prior. Of the 5871 participants, 3989 had their first vaccine dose at least 21 days before the start of the study. Participants received the Pfizer-BioNTech mRNA vaccine (BNT162b2). These participants gave blood samples, which were measured for antibody levels. The investigators utilized the UK’s SIREN (SARS-CoV-2 Infection and Reinfection and EvaluatioN) study to identify nearly 6000 healthcare workers. Ashley Otter of the UK Health Security Agency (UKHSA), sought to optimize the antibodies produced by vaccination to prevent the number of severe or fatal COVID-19 infections and prevent the virus from further mutating. Research presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, found a longer interval between COVID-19 vaccine doses can boost antibodies by 9-fold. However, new data suggests there may be benefits to waiting longer in between doses. These doses are typically given 21 days apart for Pfizer-BioNTech, and at least 24 days apart for Moderna. The current mRNA vaccines approved in the US, Pfizer-BioNTech and Moderna, both require 2 doses for a primary vaccination series.
0 kommentar(er)
